Continuous Glucose Monitoring (CGM) Market - Forecasts from 2018 to 2023

Continuous Glucose Monitoring (CGM) Market - Forecasts from 2018 to 2023

The global continuous glucose monitoring (CGM) market is projected to witness a CAGR of 20.71% during the forecast period to reach a total market size of US$3.916 billion by 2023, increasing from US$1.266 billion in 2017. Continuous glucose monitoring devices are the latest advancement in the field of diabetes management. CGM devices have the ability to alert a diabetes patient of impending hypoglycemic/ hyperglycemic events and thereby enables the patient to avoid extreme these conditions by activating the insulin pump. The demand for continuous glucose monitoring devices is increasing for diagnosis and treatment of diabetes. In addition, a rise in the diabetic population is further contributing towards the growing demand for glucose monitoring devices. Technological innovations, the convenience of the monitoring device, the early detection of hypoglycemia and hyperglycemic diabetes are some of the major drivers boosting the growth of this market.  However, high prices of these devices and calibration issues will restrict the market growth over the forecast period.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top-down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the value chain of continuous glucose monitoring (CGM) market. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Dexcom, Inc., Abbott Laboratories, Medtronic Pvt. Ltd., GlySens Incorporated, and Animas Corporation among others.

Segmentation

The continuous glucose monitoring (CGM) market has been analyzed through the following segments:

By Application

Diabetic Patients

Critical Care Patients


By End User

Hospitals

Diagnostic Centers and Clinics

Home care


By Geography

North America

USA

Canada

Mexico

Others


South America

Brazil

Argentina

Others


Europe

France

Germany

UK

Italy

Others


Middle East and Africa

UAE

Israel

Saudi Arabia

Others


Asia Pacific

China

India

Japan

South Korea

Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Currency

1.5. Assumptions

1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation

4.2. Market Drivers

4.3. Market Restraints

4.4. Market Opportunities

4.5. Porter’s Five Force Analysis

4.5.1. Bargaining Power of Suppliers

4.5.2. Bargaining Power of Buyers

4.5.3. Threat of New Entrants

4.5.4. Threat of Substitutes

4.5.5. Competitive Rivalry in the Industry

4.6. Life Cycle Analysis - Regional Snapshot

4.7. Market Attractiveness

5. CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY APPLICATION

5.1. Diabetic Patients

5.2. Critical Care Patients

6. CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY END USER

6.1. Hospitals

6.2. Diagnostic Centers and Clinics

6.3. Home Care

7. CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY GEOGRAPHY

7.1. North America

7.1.1. USA

7.1.2. Canada

7.1.3. Mexico

7.1.4. Others

7.2. South America

7.2.1. Brazil

7.2.2. Argentina

7.2.3. Others

7.3. Europe

7.3.1. France

7.3.2. Germany

7.3.3. UK

7.3.4. Italy

7.3.5. Others

7.4. Middle East and Africa

7.4.1. UAE

7.4.2. Israel

7.4.3. Saudi Arabia

7.4.4. Others

7.5. Asia Pacific

7.5.1. China

7.5.2. India

7.5.3. Japan

7.5.4. South Korea

7.5.5. Others

8. COMPETITIVE INTELLIGENCE

8.1.  Market Share Analysis

8.2.  Investment Analysis

8.3.  Recent Deals

8.4.  Strategies of Key Players

9. COMPANY PROFILES

9.1. Dexcom, Inc.

9.1.1. Company Overview

9.1.2. Financials

9.1.3. Products and Services

9.1.4. Recent Developments

9.2.  Abbott Laboratories

9.2.1. Company Overview

9.2.2. Financials

9.2.3. Products and Services

9.2.4. Recent Developments

9.3.  Medtronic Pvt. Ltd.

9.3.1. Company Overview

9.3.2. Financials

9.3.3. Products and Services

9.3.4. Recent Developments

9.4.  GlySens Incorporated

9.4.1. Company Overview

9.4.2. Financials

9.4.3. Products and Services

9.4.4. Recent Developments

9.5. Animas Corporation

9.5.1. Company Overview

9.5.2. Financials

9.5.3. Products and Services

9.5.4. Recent Developments

9.6.  Senseonics

9.6.1. Company Overview

9.6.2. Financials

9.6.3. Products and Services

9.6.4. Recent Developments

9.7. GlySure

9.7.1. Company Overview

9.7.2. Financials

9.7.3. Products and Services

9.7.4. Recent Developments

9.8. Biorasis

9.8.1. Company Overview

9.8.2. Financials

9.8.3. Products and Services

9.8.4. Recent Developments

LIST OF FIGURES

LIST OF TABLES

Dexcom, Inc.

Abbott Laboratories

Medtronic Pvt. Ltd.

GlySens Incorporated

Animas Corporation

  • SKU:
  • Publishing Date: 2018-07-31
  • Product Code: 1
  • Availability: In Stock
  • $3,950.00
  • Ex Tax: $3,950.00

Available Options